Financial News Feed

Stronger Sell Today AKBA ranks #4047 as SELL CANDIDATE. Weaker Sell
Today AKBA ranks #4047 as SELL CANDIDATE.

AKBA stock Akebia Therapeutics

AKBA stock
Akebia Therapeutics

Tracking shares of Akebia Therapeutics (AKBA), we have noted that the current price is above the Chikou. Traders following this signal will be watching for possible future upward momentum. Stock marke...

Read more

Akebia Therapeutics (NASDAQ:AKBA) was downgraded by Zacks Investment Research from a “buy” rating to a “hold” rating in a report issued on Wednesday. According to Zacks, “Akebia Therapeutics...

Read more

Here will take a quick scan of Earnings Yield information on shares of Akebia Therapeutics, Inc. (NasdaqGM:AKBA). Currently, the Earnings to Price (Yield) is -0.098640, Earnings Yield is -0.112760, an...

Read more

Interested investors might be taking a look at the medium range signals for Akebia Therapeutics (AKBA). The reading from the 40-day commodity channel index is currently Hold. The CCI indicator is main...

Read more

Shares of Akebia Therapeutics (AKBA) are heading in a near-term negative direction as the most recent close of the company has stayed below the Balance Step. The Balance Step reading takes into accoun...

Read more

Akebia Therapeutics (NASDAQ:AKBA) was upgraded by Zacks Investment Research from a “hold” rating to a “buy” rating in a note issued to investors on Tuesday. The brokerage presently has a $6.75...

Read more

Stock volatility is a percentage that indicates whether a stock is a desirable purchase. Investors look at the Volatility 12m to determine if a company has a low volatility percentage or not over the ...

Read more

Akebia Therapeutics Inc (NASDAQ:AKBA) has been given a consensus rating of “Buy” by the nine analysts that are covering the company, Marketbeat.com reports. One research analyst has rated the stoc...

Read more

Zacks Investment Research upgraded shares of Akebia Therapeutics (NASDAQ:AKBA) from a hold rating to a buy rating in a report released on Tuesday morning. Zacks Investment Research currently has $6.75...

Read more

After a recent scan, we can see that Akebia Therapeutics, Inc. (NasdaqGM:AKBA) has a Shareholder Yield of -0.209836 and a Shareholder Yield (Mebane Faber) of -1.47280. The first value is calculated by...

Read more

Akebia Therapeutics, Inc. (NasdaqGM:AKBA) boasts a Price to Book ratio of 4.961165. This ratio is calculated by dividing the current share price by the book value per share. Investors may use Price to...

Read more

Investors sentiment decreased to 0.89 in Q3 2018. Its down 0.46, from 1.35 in 2018Q2. It fall, as 19 investors sold Akebia Therapeutics, Inc. shares while 36...

Read more

Following the trading signals on shares of Akebia Therapeutics (AKBA), we note that the twenty one day Wilder Moving Average is currently under the 50 day Simple Moving Average. Traders may use this r...

Read more

Traders will be closely monitoring shares of Akebia Therapeutics (AKBA) as the Twiggs Money Flow indicator has ducked below the zero line, indicating possible downward momentum for the name. When Twig...

Read more

Akebia Therapeutics, Inc. (NasdaqGM:AKBA) has a Piotroski F-Score of 5 at the time of writing. The F-Score may help discover companies with strengthening balance sheets. The score may also be used to ...

Read more

News Feed powered by

Proudly made at

Rise Vilnius
in partnership with
Barclays Bank